The University of California, Irvine's (UCI) Gynecologic Oncology Fellowship Program is requesting continued support for the Fellowship Training Program, which has been operating for over 30 years, and has been supported for 20 years by this T32 grant. The training grant is administered by UCI's Department of Obstetrics and Gynecology and Division of Gynecology Oncology. The Gynecologic Oncology Fellowship Program is dedicated to training physician scientists in the sub-specialty of Gynecologic Oncology by providing multiple levels of interaction between basic and clinical scientists to facilitate the transfer and exchange of information. The Fellowship Program provides trainees with opportunities for the practical application of skills in the design and testing of scientific hypotheses. Trainees receive two years of laboratory research training in the basic sciences followed by two years of clinical training, with a focus on clinical/translational research. There are twenty faculty mentors, made up of basic scientists and clinical researchers from eleven departments in the School of Biological Sciences and School of Medicine. Faculty Mentors have research concentrations in the following areas: tumor angiogenesis, developmental therapeutics, experimental medicine, oncologic signal transduction pathways, carcinogenesis, psycho-social and neuro-immunologic function, epidemiology and healthcare disparities, survivorship medicine, and in-vivo functional onco-imaging. All of the training faculty have active, peer-reviewed research grants directly relevant to cancer research, or cancer- related. Competition is keen for the one or two available entry-level Fellowship positions annually. Recruitment for the Fellowship Program draws from the 1,200 Obstetrics and Gynecology senior residents nationwide. Over 95% of the graduates from the UC Irvine Gynecologic Oncology Fellowship Program have assumed academic faculty positions (see Table 12B). Training features of the program include didactic coursework in the areas of responsible conduct of research, biostatistics and epidemiology, fundamentals of gynecologic oncology, evidence-based medicine in gynecologic oncology, and cancer-related electives, national scientific meetings, and numerous other multi-disciplinary seminars, lectures and symposia. Support is requested for three Postdoctoral Fellowship positions in each year of the grant. Fellows will be supported by funds from the training grant for the first two years, with supplemental support from the Department of Obstetrics and Gynecology. The Department of Obstetrics and Gynecology will fully support fellows in years three and four of their training.
The Fellowship Program will train the physician scientists in the field of Gynecological Oncology for future generations of not only grateful cancer patients but for future medical students and residents interested in both the discovery of cures for different gynecologic cancers and the realization of meaningful quality of life among survivors. Our graduates will continue to be distinguished members of the academic medical field, leading and contributing to new advances in diagnosis and treatment of gynecologic cancer as both translational scientists and academic surgeons.
|Wolford, Juliet E; Tewari, Krishnansu S (2018) Rational design for cervical cancer therapeutics: cellular and non-cellular based strategies on the horizon for recurrent, metastatic or refractory cervical cancer. Expert Opin Drug Discov 13:445-457|
|Minion, Lindsey E; Tewari, Krishnansu S (2018) Cervical cancer - State of the science: From angiogenesis blockade to checkpoint inhibition. Gynecol Oncol 148:609-621|
|Pfaendler, Krista S; Chang, Jenny; Ziogas, Argyrios et al. (2018) Disparities in Adherence to National Comprehensive Cancer Network Treatment Guidelines and Survival for Stage IB-IIA Cervical Cancer in California. Obstet Gynecol 131:899-908|
|Wolford, Juliet E; Tewari, Krishnansu S (2017) Highlights from the Gynecologic Oncology Track at the 2017 Annual Meeting of the American Society of Clinical Oncology. J Gynecol Oncol 28:e74|
|Pfaendler, Krista S; Tewari, Krishnansu S (2016) Changing paradigms in the systemic treatment of advanced cervical cancer. Am J Obstet Gynecol 214:22-30|
|Eskander, Ramez N; Ali, Shamshad; Dellinger, Thanh et al. (2016) Expression Patterns of the Wnt Pathway Inhibitors Dickkopf3 and Secreted Frizzled-Related Proteins 1 and 4 in Endometrial Endometrioid Adenocarcinoma: An NRG Oncology/Gynecologic Oncology Group Study. Int J Gynecol Cancer 26:125-32|
|Longoria, Teresa C; Tewari, Krishnansu S (2016) Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma. Expert Opin Drug Metab Toxicol 12:1247-53|
|Eskander, Ramez N; Tewari, Krishnansu S (2015) Development of bevacizumab in advanced cervical cancer: pharmacodynamic modeling, survival impact and toxicology. Future Oncol 11:909-22|
|Liu, Fong W; Galvan-Turner, Valerie B; Pfaendler, Krista S et al. (2015) A critical assessment of morcellation and its impact on gynecologic surgery and the limitations of the existing literature. Am J Obstet Gynecol 212:717-24|
|Galvan-Turner, Valerie B; Chang, Jenny; Ziogas, Argyrios et al. (2015) Observed-to-expected ratio for adherence to treatment guidelines as a quality of care indicator for ovarian cancer. Gynecol Oncol 139:495-9|
Showing the most recent 10 out of 25 publications